enfr

SCN 2018-19 Funding Results: Clinical Trials

Principal InvestigatorCo-InvestigatorProject TitleSCN Funds Allocated
Jean Roy – Hôpital
Maisonneuve-
Rosemont (HMR)
Guy Sauvageau (UdeM), Jean-Sebastien Delisle (HMR), Richard Leblanc (HMR), Sandra Cohen (HMR), Silvy Lachance (HMR), Imran Ahmad (HMR), Émilie Lemieux-Blanchard (CRCHUM), Michael Sebag (MUHC), Sebastien Lemieux (UdeM), Gabriel Tremblay (Geneconomic)Allogeneic stem cell transplant using UM171 expanded cord bloods for patients with high-risk multiple myeloma$500,000
James Shapiro – U of APeter Senior (U of A), Peter Light (U of A), Gregory Korbutt (U of A), Eugene Brandon (Viacyte Inc.), Kevin D’Amour (Viacyte Inc.), Howard Foyt (Viacyte Inc.), Sylvain Bedard (CEPPP), Bart Roep (U Leiden), Joanna Preston (TEC Edmonton), Chris McCabe (U of A)Pancreatic Progenitor Cell Therapy: Solving Supply and Survival Issues of Islet Cell Transplantation for T1DM$500,000
Duncan Stewart – OHRIDavid Courtman (GMP Facility OHRI), Michael Kutryk (SMH), Chris Glover (UOHI), Hung-Ly Quoc (MHI), Alexander Dick (UOHI), Michel Lemay (UOHI), Kim Connelly (SMH), Howard Leong Poi (SMH), Josep Rodes-Cabau (U Laval), Dominique Joyal (JGH)Enhanced Angiogenic Cell Therapy for Acute Myocardial Infarction (ENACT-AMI)$500,000

Clinical Trials Summary

Applications ReceivedApplications Recommended for FundingPercentage of Successful ApplicationsTotal Investment
4375%$1.5 million

SCN 2018-19 Funding Results: Disease Team Program

Principal InvestigatorCo-InvestigatorProject TitleSCN Funds Allocated
Gilbert Bernier – Hôpital
Maisonneuve-
Rosemont (HMR)
May Griffith (UdeM), Jean-Francois Bouchard (UdeM), Flavio Rezende (HMR), Cynthia Qian (UdeM), Mario Filion (INRS)Macula transplantation for the treatment of retinal degenerative diseases$200,000
Joanna Matsubara – UBCMarinko Sarunic (SFU), David Maberly (UBC), Orson Moritz (UBC), Arif Samad (DU), Sean Lumb (UBC)Treating advanced retinal degeneration – rebuilding multiple co-dependent retinal layers with stem cells$100,000
Lauralyn McIntyre – OHRIShirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (Hamilton Health Sciences Corporation), Margaret Herridge (UHN), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI), Dana Devine (CBS)Cellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial$200,000
Freda Miller – The Hospital for Sick Children (HSC)Donald Mabbott (HSC), David Kaplan (HSC), Cindi Morshead (U of T), Jing Wang (OHRI), Ann Yeh (HSC), Douglas Munoz (Queens U), Paul Frankland (HSC), Wolfram Tetzlaff (UBC), Brian Nieman (HSC)Pharmacological recruitment of endogenous neural precursors to promote pediatric white matter repair$200,000
Massimiliano Paganelli – CHU Sainte-Justine, UdeMElie Haddad (UdeM), Christian Beausejour (UdeM), Ariella Shikanov (U of Michigan), Serge McGraw (UdeM), Yves Théoret (CHU Sainte-Justine), Michel Lallier (CHU Sainte-Justine)

Safety and efficacy of stem cell-derived encapsulated liver tissue to treat liver failure without immunosuppression$100,000
James Shapiro – U of AGregory Korbutt (U of A), ViaCyte Inc., Joanna Preston (TEC Edmonton), Peter Senior (U of A), Bruce Verchere (UBC)Development of a novel stem cell-derived transplant modality for type 1 diabetes$100,000
Bruce Verchere – UBCFrancis Lynn (UBC), Megan Levings (UBC), Tim Kieffer (UBC), Dina Panagiotopoulos (UBC), Brad Hoffman (UBC), Garth Warnock (UBC), Gregory Korbutt (UofA)Genetic manipulation of hES-derived insulin-producing cells to improve graft outcomes$200,000

Disease Team Program Summary

Applications ReceivedApplications Recommended for FundingPercentage of Successful ApplicationsTotal Investment
11764%$1.1 million

SCN 2018-19 Funding Results: Impact Research Program

InvestigatorsProject Stream Project TitleSCN Funds Allocated
Florian Bentzinger – UdeSherbrooke
(Principal Investigator)

Eric Marsault (UdeSherbrooke), Mannix Auger-Messier (UdeSherbrooke), Nicolas Dumont (CHU-Sainte-Justine, UdeM), Frederic Balg (UdeSherbrooke)
Discovery TranslationApelinergic Compounds for the treatment of muscular dystrophy$99,000
Mick Bhatia – McMaster
(Principal Investigator)

Rima Al-Awar (OICR)
Discovery TranslationIdentification of kinases and their target substrates in early human PSC specification$100,000
Timothy Caulfield – U of A
(Principal Investigator)

Amy Zarzeczny (UofR), Barbara von Tigerstrom (UofA), Tania Bubela (SFU), Yann Joly (McGill), Zubin Master (Mayo Clinic), Jeremy Snyder (SFU), Ubaka Ogbogu (UofA)
Public PolicyThe Next Step: Specific Strategies for Addressing the Marketing of Unproven Stem Cell Therapies$40,000
Nicolas Dumont – CHU Sainte-Justine, UdeM (Principal Investigator)

Sylvie Girard (UdeM), Cam-Tu Nguyen (UdeM), Phillipe Campeau (UdeM), Christian Beauséjour (UdeM)
Discovery TranslationTargeting muscle stem cells to mitigate Duchenne muscular dystrophy$100,000
John Hassell – McMaster
(Principal Investigator)

Rima Al-awar (OICR)
Discovery TranslationHTR5A as a target for anticancer stem cell drug discovery$99,500
Timothy Kieffer – UBC
(Principal Investigator)

Ali Rezania (Viacyte Inc.)
Clinical Translation & AcceleratorAssessment of Cell Maturation and Function in Subcutaneous Macroencapsulation Devices in Rodents$100,000
Bartha Knoppers – McGill
(Principal Investigator)

Rosario Isai (OHRI), Tim Caulfield (UofA), Amy Zarzeczny (UofR), Tania Bubela (SFU), Ubaka Ogbogu (UofA), Vardit Ravitsky (UdeM)
Public PolicyReforming Canadian Stem Cell Policy: Moving Beyond the Assisted Human Reproduction Act (AHRA)$39,736
Zachary Laksman – UBC
(Principal Investigator)

Glen Tibbits (SFU)
Clinical Translation & AcceleratorUsing stem cells to test new drugs for atrial fibrillation$100,000
Lauralyn McIntyre – OHRI
(Principal Investigator)

Shirley Mei (OHRI), Duncan Stewart (OHRI), Dean Fergusson (OHRI), John Marshall (SMH), Keith Walley (UBC), Claudia dos Santos (SMH), Brent Winston (U of C), Shane English (OHRI), Alexis Turgeon (U Laval), Geeta Mehta (U of T), Robert Green (DU), Alison Fox-Robichaud (McMaster), Margaret Herridge (U of T), John Granton (U of T), Paul Hebert (CRCHUM), Kednapa Thavorn (OHRI), Timothy Ramsay (OHRI), David Courtman (GMP Facility OHRI)
Clinical Translation & AcceleratorCellular Immunotherapy for Septic Shock (CISS2): A Phase II Multicentre Clinical Trial$100,000
Derrick Rancourt – UC
(Principal Investigator)

Eric Jervis (STEMCELL Technologies)
CommercializationEnhancing the Efficiency of Genome Engineering in Human Pluripotent Stem Cells$100,000
Bernard Thébaud – OHRI
(Principal Investigator)

Mervin Yoder (Hospital for Children, Indianapolis), Dylan Burger (U of O)
Clinical Translation & AcceleratorEndothelial Progenitor Cell-derived Therapies for Neonatal Pulmonary Hypertension$99,905
Glen Tibbits – SFU
(Principal Investigator)

Thomas Claydon (SFU), Zachary Laksman (UBC), Shubhayan Sanatani (UBC)
Clinical Translation & AcceleratorDeveloping an hiPSC-CM based protocol to investigate SIDS-implicated sudden cardiac arrest in infants$99,500
Eve Tsai – OHRI
(Principal Investigator)

Xudong Cao (U of O), Ruth Slack (U of O)
Clinical Translation & AcceleratorTranslating an animal endogenous stem/progenitor cell repair strategy for stroke to humans$100,000
Peter Zandstra – UBC
(Principal Investigator)

Fiona Watt (King’s College, London, UK), Davide Danovi (King’s College, London, UK)
CommercializationA robust, quantitative, and high-throughput assay to rapidly characterize human induced pluripotent stem cells$100,000

Impact Research Program Summary

Applications ReceivedApplications Recommended for FundingPercentage of Successful ApplicationsTotal Investment
461430%$1.4 million

* Project titles posted as per the language of submission

SCN 2016 funding results

View PDF